Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Adherium Limited

- PMLiVE

New £5m project launched to bring Alzheimer’s blood tests to the NHS

Blood tests for the condition could become available on the NHS within five years

- PMLiVE

UK antibiotic subscription model found by OHE as key to supporting investment

The OHE report offers valuable insights into investor views of the subscription model

- PMLiVE

Novartis’ Cosentyx recommended by NICE for hidradenitis suppurativa

At least 200,000 people in the UK are affected by the inflammatory skin disease

- PMLiVE

Life sciences leaders warn against ‘unworkable’ changes to UK medicines scheme

The scheme could impact UK life sciences and NHS patient access to medicines

- PMLiVE

NHS expands diagnostic capabilities to reform cancer standards for patients

Thousands of patients are set to receive faster diagnosis and treatment

- PMLiVE

NHS achieves new record for cancer checks for patients

Nearly three million patients have had cancer checks by the NHS in the last year

- PMLiVE

NHS to initiate flu vaccine roll-outs for children from September

The roll-outs are part of the NHS winter flu and COVID-19 vaccination programme

- PMLiVE

New NHS treatments increase survival rates for babies with spinal muscular atrophy

Around 70 babies are born with the rare muscle-wasting disease each year in the UK

- PMLiVE

NHS extends eligibility for shingles vaccine to almost one million people

Approximately one in four people will develop shingles and the risk increases with age

- PMLiVE

Bristol Myers Squibb’s Sotyktu recommended by NICE for plaque psoriasis

An estimated 1.8 million people in the UK are affected by some form of the condition

- PMLiVE

NHS to introduce world-first genetic blood-matching test for transfusion treatments

NHS Blood and Transplant will receive almost £1m in funding from NHS England

- PMLiVE

NHS spring COVID-19 booster programme opens up for those at highest risk

Around five million people are eligible for the booster in line with the JCVI’s advice

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links